PSP Research LLC Makes New Investment in Roivant Sciences Ltd. $ROIV

PSP Research LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 24,621 shares of the company’s stock, valued at approximately $534,000.

A number of other hedge funds also recently bought and sold shares of ROIV. Vanguard Group Inc. raised its stake in shares of Roivant Sciences by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after acquiring an additional 3,254,113 shares during the period. Rubric Capital Management LP raised its stake in shares of Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after acquiring an additional 2,603,260 shares during the period. State Street Corp raised its stake in shares of Roivant Sciences by 4.8% in the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after acquiring an additional 911,827 shares during the period. UBS Group AG raised its stake in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Roivant Sciences by 18.0% in the third quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company’s stock valued at $140,839,000 after acquiring an additional 1,423,074 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Down 1.2%

NASDAQ ROIV opened at $28.21 on Wednesday. The company’s 50-day moving average price is $28.38 and its 200-day moving average price is $24.85. The stock has a market cap of $20.19 billion, a PE ratio of -24.11 and a beta of 1.14. Roivant Sciences Ltd. has a 12 month low of $10.59 and a 12 month high of $30.33.

Insider Transactions at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $29.59, for a total value of $5,918,000.00. Following the transaction, the chief executive officer directly owned 1,647,546 shares in the company, valued at approximately $48,750,886.14. This represents a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Gline sold 289,774 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the completion of the transaction, the chief executive officer owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. The trade was a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 3,745,173 shares of company stock valued at $103,639,917. Company insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ROIV. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Piper Sandler increased their target price on shares of Roivant Sciences from $22.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 16th. Guggenheim increased their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Finally, Sanford C. Bernstein started coverage on shares of Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.55.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.